UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

Pediatrics (Evanston), 2006-11, Vol.118 (5), p.2135-2145

2006

Volltextzugriff (PDF)

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial

The Pediatric infectious disease journal, 2007-03, Vol.26 (3), p.201-209

2007

Volltextzugriff (PDF)

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years

24th International Papillomavirus Conference and Clinical Workshop,2007-11-03 - 2007-11-09, 2009-04, Vol.199 (7), p.926-935

2009

Volltextzugriff (PDF)

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

24th International Papillomavirus Conference and Clinical Workshop,2007-11-03 - 2007-11-09, 2009-04, Vol.199 (7), p.936-944

2009

Volltextzugriff (PDF)

Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

International journal of cancer, 2011-12, Vol.129 (11), p.2632-2642

2011

Volltextzugriff (PDF)

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

JNCI : Journal of the National Cancer Institute, 2010-03, Vol.102 (5), p.325-339

2010

Volltextzugriff (PDF)

Using proportion of similar response to evaluate correlates of protection for vaccine efficacy

Statistical methods in medical research, 2015-04, Vol.24 (2), p.273-286

2015

Volltextzugriff (PDF)

M-M-R®II manufactured using recombinant human albumin (rHA) and M-M-R®II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

Vaccine, 2015-04, Vol.33 (18), p.2132-2140

2015

Volltextzugriff (PDF)

A Bayesian approach for evaluating equivalence over multiple groups, and comparison with frequentist tost

Journal of applied statistics, 2024, Vol.51 (12), p.2382-2401

2024

Volltextzugriff (PDF)

A Quality By Design Approach For Longitudinal Quality Attributes

Journal of biopharmaceutical statistics, 2015-03, Vol.25 (2), p.247-259

2015

Volltextzugriff (PDF)

M-M-R?IImanufactured using recombinant human albumin (rHA) and M-M-R?IImanufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

Vaccine, 2015-04, Vol.33 (18), p.2132

2015

Volltextzugriff (PDF)

M-M-R registered II manufactured using recombinant human albumin (rHA) and M-M-R registered II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

Vaccine, 2015-04, Vol.33 (18), p.2132-2140

2015

Volltextzugriff (PDF)

Statistics for Biotechnology Process Development

1, 2018

Volltextzugriff (PDF)

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

Vaccine, 2004-07, Vol.22 (21), p.2943-2952

2004

Volltextzugriff (PDF)

Bayesian Prediction for Staged Testing Procedures

Case Studies in Bayesian Methods for Biopharmaceutical CMC, 2023, Vol.1, p.135-148

1, 2023

Volltextzugriff (PDF)

Bayesian Statistics for Manufacturing

Bayesian Methods in Pharmaceutical Research, 2020, p.449-464

1, 2020

Volltextzugriff (PDF)

Continued Process Verification

Statistics for Biotechnology Process Development, 2018, Vol.1, p.253-272

1, 2018

Volltextzugriff (PDF)

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(17)

Publikationsform

Sprache

Englisch
(19)
Japanisch
(6)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years

The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16–26 Years

Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection

Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women

Using proportion of similar response to evaluate correlates of protection for vaccine efficacy

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

M-M-R®II manufactured using recombinant human albumin (rHA) and M-M-R®II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

A Bayesian approach for evaluating equivalence over multiple groups, and comparison with frequentist tost

A Quality By Design Approach For Longitudinal Quality Attributes

M-M-R?IImanufactured using recombinant human albumin (rHA) and M-M-R?IImanufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

M-M-R registered II manufactured using recombinant human albumin (rHA) and M-M-R registered II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children

Statistics for Biotechnology Process Development

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

Bayesian Prediction for Staged Testing Procedures

Bayesian Statistics for Manufacturing

Continued Process Verification

Suchergebnisse filtern